Cite
HARVARD Citation
Geva, R. et al. (2020). First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer. 126 (22), pp. 4926-4935. [Online].